SCHEMBL6461833

SCHEMBL6461833

Cc1cc(NC2CCC(NC(=O)c3ccc(F)c(Cl)c3)CC2)nc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 11/20 0.55
ADRA2A P08913 8/20 0.55
HRH1 P35367 2/20 0.55
HTR2B P41595 2/20 0.55
HTR1A P08908 1/20 0.55
ADRA1A P35348 1/20 0.55
NPY5R Q15761 1/20 0.55
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
AR P10275 3/20 0.47
RAB9A P51151 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6456287 1.00 MCHR1 (0.55) MCHR1ADRA2AHRH1HTR2BHTR1A
Hydrochloric Acid SCHEMBL6461477 0.99 MCHR1 (0.54) MCHR1ADRA2AHRH1HTR2BHTR1A
Hydrochloric Acid SCHEMBL6461474 0.99 MCHR1 (0.54) MCHR1ADRA2AHRH1HTR2BHTR1A
SCHEMBL6464755 0.96 MCHR1 (0.52) MCHR1ADRA2AHRH1HTR2BHTR1A
SCHEMBL6464760 0.96 MCHR1 (0.52) MCHR1ADRA2AHRH1HTR2BHTR1A
SCHEMBL6456066 0.92 MCHR1 (0.55) MCHR1ADRA2AHRH1HTR2BHTR1A
SCHEMBL6456060 0.92 MCHR1 (0.55) MCHR1ADRA2AHRH1HTR2BHTR1A
Hydrochloric Acid SCHEMBL6455726 0.91 MCHR1 (0.54) MCHR1ADRA2AHRH1HTR2BHTR1A
Hydrochloric Acid SCHEMBL6455718 0.91 MCHR1 (0.54) MCHR1ADRA2AHRH1HTR2BHTR1A
SCHEMBL6465690 0.91 ADRA2A (0.66) MCHR1ADRA2AHRH1HTR2BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 MCHR1 2/4885ADRA2A 117/4885HRH1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.